200,000+ products from a single source!
sales@angenechem.com
Home > Sulfanilamide > 342005-82-7
342005-82-7 | Ethenesulfonamide, N-[6-methoxy-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-2-phenyl-, potassium salt (1:1), (1E)-
CAS No: 342005-82-7 Catalog No: AG00JOHJ MDL No:
Product Description
Catalog Number:
AG00JOHJ
Chemical Name:
Ethenesulfonamide, N-[6-methoxy-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-2-phenyl-, potassium salt (1:1), (1E)-
CAS Number:
342005-82-7
Molecular Formula:
C24H20KN5O5S
Molecular Weight:
529.6094
IUPAC Name:
potassium;[6-methoxy-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]-[(E)-2-phenylethenyl]sulfonylazanide
InChI:
InChI=1S/C24H20N5O5S.K/c1-32-18-11-6-7-12-19(18)34-20-21(29-35(30,31)16-13-17-9-4-3-5-10-17)27-23(28-24(20)33-2)22-25-14-8-15-26-22;/h3-16H,1-2H3;/q-1;+1/b16-13+;
InChI Key:
WOPWEXSDEXIRNG-ZUQRMPMESA-N
SMILES:
COc1nc(nc(c1Oc1ccccc1OC)[N-]S(=O)(=O)/C=C/c1ccccc1)c1ncccn1.[K+]
UNII:
OK6K3MDZ98
Properties
Complexity:
773
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1
Exact Mass:
529.082g/mol
Formal Charge:
0
Heavy Atom Count:
36
Hydrogen Bond Acceptor Count:
10
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
529.612g/mol
Monoisotopic Mass:
529.082g/mol
Rotatable Bond Count:
9
Topological Polar Surface Area:
123A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| In vitro and in vivo effects of endothelin-1 and YM598, a selective endothelin ET A receptor antagonist, on the lower urinary tract. | European journal of pharmacology 20080212 |
| Endothelin receptor antagonists in cancer therapy. | Cancer investigation 20071201 |
| Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy. | Vascular pharmacology 20070601 |
| Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line. | Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20070101 |
| A novel and selective endothelin ET(A) receptor antagonist YM598 prevents the development of chronic hypoxia-induced pulmonary hypertension in rats. | Vascular pharmacology 20050601 |
| YM598, an orally active ET(A) receptor antagonist, ameliorates the progression of cardiopulmonary changes and both-side heart failure in rats with cor pulmonale and myocardial infarction. | Journal of cardiovascular pharmacology 20041101 |
| Pharmacological characterization of YM598, a selective endothelin-A receptor antagonist. | Journal of cardiovascular pharmacology 20041101 |
| Renal protective effect of YM598, a selective endothelin type A receptor antagonist. | Journal of cardiovascular pharmacology 20041101 |
| Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. | Journal of cardiovascular pharmacology 20041101 |
| Chronic administration of an endothelin-A receptor antagonist improves exercise capacity in rats with myocardial infarction-induced congestive heart failure. | Journal of cardiovascular pharmacology 20041101 |
| Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist. | European journal of pharmacology 20040913 |
| The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. | European journal of pharmacology 20040802 |
| Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. | European journal of pharmacology 20040525 |
| Effect of single oral administration of YM598, a novel selective endothelin ETA receptor antagonist, on blood pressure in normotensive and hypertensive rats. | Vascular pharmacology 20040201 |
| Endothelin receptor antagonists in the treatment of prostate cancer. | Seminars in oncology 20031001 |
| Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET(A) receptor antagonist. | European journal of pharmacology 20030930 |
| Renal protective effect of YM598, a selective endothelin ET(A) receptor antagonist, against diabetic nephropathy in OLETF rats. | European journal of pharmacology 20020823 |
| Ethenesulfonamide and ethanesulfonamide derivatives, a novel class of orally active endothelin-A receptor antagonists. | Bioorganic & medicinal chemistry 20011101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.